Ampicillin/sulbactam: Its potential use in treating infections in critically ill patients
Author:
Publisher
Elsevier BV
Subject
Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine
Reference75 articles.
1. US Food and Drug Administration. Unasyn (ampicillin/sulbactam): detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER)—April 2008.
2. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008–2009);Hawser;Clin Microbiol Infect,2011
3. Clinical characteristics of bloodstream infections due to ampicillin–sulbactam-resistant, non-extended-spectrum-β-lactamase-producing Escherichia coli and the role of TEM-1 hyperproduction;Waltner-Toews;Antimicrob Agents Chemother,2011
4. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam;Levin;Int J Antimicrob Agents,2003
5. High-dose ampicillin–sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii;Betrosian;Scand J Infect Dis,2007
Cited by 45 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. TEMPO-oxidized nanofibrillated cellulose as potential carrier for sustained antibacterial delivery;International Journal of Biological Macromolecules;2024-01
2. Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections;Annals of Pharmacotherapy;2023-10-10
3. Sulbactam‐durlobactam: A novel β‐lactam‐β‐lactamase inhibitor combination targeting carbapenem‐resistant Acinetobacter baumannii infections;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2023-05-23
4. The clinical and paraclinical effectiveness of four-hour infusion vs. half-hour infusion of high-dose ampicillin-sulbactam in treatment of critically ill patients with sepsis or septic shock: An assessor-blinded randomized clinical trial;Journal of Critical Care;2023-02
5. HPTLC/MS and HPTLC/UV for monitoring of degradation behavior of some β-Lactam antibiotics mixtures under ambient storage conditions;Microchemical Journal;2023-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3